Catalyst Pharmaceuticals Announces Positive Data from Investigator-Sponsored Trial of Firdapse ® in treating MuSK Antibody Positive Myasthenia Gravis
Catalyst intends to proceed to U.S. multi-center pivotal trial
Expects additional data to be presented at upcoming medical congresses in 2017
CORAL GABLES, Fla., March 15, 2017 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare neuromuscular and neurological diseases, today announced positive top-line results from the investigator-sponsored trial evaluating Firdapse® (Amifampridine Phosphate) as a treatment for myasthenia gravis patients with anti-MuSK antibodies (MuSK-MG).
- Published: 15 March 2017
- Written by Editor